Ninety-five patients with chronic hepatitis C virus (HCV) infection, 35 with persistently normal serum alanine aminotransferase (ALT) levels, were randomized to treatment with daily interferon (IFN) for 3 months, followed by IFN 3 times weekly (TIW) for 12 months (group A) or TIW for 18 months (group B). Patients with elevated versus normal ALT levels had similar demographic and virologic characteristics but significantly ( ) more advanced P ! .05 liver histology (bridging fibrosis and cirrhosis, 37.9% vs. 11.4%). After 3 months of treatment, 38.3% of patients in group A were HCV RNA negative versus 18.8% in group B ( ). P ! .05 When the IFN dose was reduced from daily to TIW in group A, the percentage of patients who remained HCV RNA negative declined; sustained virologic response was similar in both groups (10.6% vs. 8.3%). Response to treatment was similar in patients with elevated or normal ALT levels. Persons with chronic HCV infection and persistently normal serum ALT levels have milder liver disease than, and respond to IFN therapy similarly to, persons with elevated ALT levels.
An estimated 20%-33% of patients with chronic hepatitis C virus (HCV) infection have persistently normal values for serum alanine aminotransferase (ALT) [1] [2] [3] [4] [5] [6] . Previous study results have suggested that these patients have only mild hepatitis and that they may either not progress to cirrhosis at all or progress at a much slower rate than persons with elevated serum ALT levels [5] [6] [7] [8] [9] . Some investigators have referred to such persons as healthy HCV carriers [2, 3] . In a recent large case-controlled trial that compared the virologic and histologic features of such patients with those of a matched population with elevated serum ALT levels [7] , persons with persistently normal ALT levels had, on average, lower serum HCV RNA levels and significantly less inflammation and fibrosis than did patients with elevated serum ALT levels. However, in this and other studies of persons with persistently normal serum ALT levels [6] [7] [8] [9] [10] [11] , liver biopsy revealed cirrhosis in 5%-10%, suggesting that this clinical scenario is not necessarily benign.
Interferon (IFN)-a with or without ribavirin remains the only therapy with proven benefit for the treatment of chronic HCV [12] [13] [14] [15] [16] [17] . Unfortunately, only 33%-50% of patients clear HCV RNA during treatment; long-term sustained virologic response is observed in only ∼35% of patients treated with IFN ribavirin and in 10% of persons treated with IFN monotherapy. In an attempt to achieve greater long-term viral eradication, various studies have examined the effects of increasing the IFN dose or dosing frequency. The results from many of these studies were recently summarized [18] . Few studies have evaluated the effectiveness of IFN in persons with persistently normal serum ALT levels [19] [20] [21] [22] [23] , and it is unclear if patients with persistently normal serum ALT levels respond to IFN as well as patients with elevated ALT levels do, if predictors of sustained response (as recently identified for persons with elevated ALT levels [24, 25] ) could be applied to patients with normal ALT levels, or if a more intensive IFN treatment regimen might be more successful in achieving sustained virologic response in this population. To answer these questions, we designed a randomized controlled trial to compare the effects of daily versus 3 times a week (TIW) IFN dosing in persons with either elevated or persistently normal serum ALT levels. 
Patients and Methods
Patient population. We evaluated 95 consecutive patients who presented to the Hepatology Section, Medical College of Virginia Commonwealth University, for evaluation and treatment of chronic HCV infection. All were anti-HCV positive by second-generation ELISA, had a positive reaction by recombinant immunoblot assay, and were positive by an HCV RNA-sensitive polymerase chain reaction (PCR) assay. Patients with any other cause of chronic hepatitis were excluded from this study by appropriate serologic testing and histologic examination of liver tissue. All patients were negative for hepatitis B surface antigen, had either negative or insignificant elevations in serum titers of anti-nuclear antibody and anti-smooth muscle antibody (р1:80), and had normal values for serum a-1-antitrypsin and ceruloplasmin. Subjects with elevations in serum iron saturation and/or ferritin had liver tissue analyzed for iron content. All patients with у2 ϩ iron by Prussian blue staining within the histologic specimen were excluded from this study. Patients were also excluded from participation if they were known to be actively using injection drugs or were consuming alcohol on a regular basis, were human immunodeficiency virus positive, were pregnant, had chronic renal failure, or had received an organ transplant. Patients with cirrhosis were enrolled in the study. However, laboratory values for serum albumin, direct bilirubin, and prothrombin time had to be within the limits of normal, and platelet and total white cell counts at baseline had to be 190,000 and 12500/ mm 3 , respectively. Study design. Consecutive patients referred to our center were divided into 2 groups, normal or elevated ALT levels, on the basis of a review of their medical records. All records for each patient enrolled in the study were obtained from the referring physicians or primary care providers. Patients were categorized as "normal ALT" only if all values for serum ALT ever obtained, dating back у6 months, were within the limits of normal. Patients with even a single value for serum ALT above the limits of normal shown at any time in the medical records were categorized as "elevated ALT." Patients within each of the 2 groups were then randomly assigned to treatment with 1 of 2 dose regimens of IFN-a-2a (Roche Laboratories, Nutley, NJ), as described below.
Group A. Patients were treated with 6 million units (MU) of IFN administered daily for 3 months. Treatment was discontinued in all persons who remained HCV RNA positive after 3 months of daily therapy. At 3 months, subjects who were HCV RNA negative had IFN dosing reduced from 6 MU daily to 6 MU TIW. This dose was continued for another 3 months. Treatment was discontinued in all patients who were HCV RNA positive after 6 months of therapy. At 6 months, for subjects who were HCV RNA negative, the dose of IFN was reduced to 3 MU TIW, and they were treated for an additional 12 months. Thus, patients who remained HCV RNA negative throughout the study received IFN for 18 months. After discontinuation of therapy, all subjects were followed up for an additional 6 months, at which point their study participation was complete.
Group B. In group B, subjects were treated with 6 MU TIW for 6 months. Treatment was discontinued in all subjects who remained HCV RNA positive at 6 months, but those who remained HCV RNA negative at 6 months had their dose of IFN reduced to 3 MU TIW and were treated for an additional 12 months. Thus, persons who remained HCV RNA negative throughout treatment received IFN for 18 months. After discontinuation of therapy, all patients were followed up for an additional 6 months, when their study participation was complete.
Laboratory studies and liver histology. Serum ALT levels, total white blood cell count, absolute polymorphonuclear lymphocyte cell count, hemoglobin, and platelet count were monitored at baseline and monthly throughout the study. Serum HCV RNA titer was measured by the Amplicor PCR assay (Roche Molecular Systems, Branchburg, NJ) at baseline and at 3-month intervals throughout the study. The lower limit for detection of HCV RNA by this assay was set in our laboratory at 500 copies/mL [26] . HCV genotype was determined by the InnoLipa assay (Innogenetics, Ghent, Belgium) [27] .
All patients had a liver biopsy within 1 year of study entry. All liver biopsy specimens were reviewed by a single pathologist (M.J.C.) and were assigned a numeric score, according to the histologic activity index of Knodell et al. [28] . Two biopsy specimens were of insufficient size for assignment of a numeric score.
Statistical analysis. Values for age, serum ALT, serum HCV RNA, and histologic activity index were reported as . mean ‫ע‬ SE Data for serum HCV RNA were first converted to a log scale. Analysis of variance, the Mann-Whitney U test, or the log-rank test was used, as appropriate, to determine whether any observed differences in these parameters between patient or treatment groups were significant. The x 2 analysis or Fisher's exact test was used to determine whether the numbers of patients who achieved virologic response at various time intervals during and after treatment were statistically different from one another. All randomized patients were included in an intention-to-treat analysis.
Results
Comparison of patients with normal and elevated serum ALT levels. Table 1 summarizes demographic characteristics and Figure 1 . Distribution of hepatic fibrosis in patients with chronic hepatitis C virus infection and normal or persistently elevated serum alanine aminotransferase (ALT) levels. Minimal hepatitis was defined as evidence of portal inflammation without piecemeal necrosis or fibrosis. Liver biopsy was inadequate to assess hepatic fibrosis in 2 patients with normal serum ALT levels. biochemical, virologic, and histologic data for patients with elevated and persistently normal serum ALT levels. The mean number of normal ALT values identified in these patients was , and these laboratory tests dated back a mean of 2.2 4.3 ‫ע‬ 2.1 years (range, 6 months-8 years).
The mean age for all patients was years; 49.5% 43.2 ‫ע‬ 0.9 were men and 52.6% were white. No significant differences were observed in mean age, sex, or race between the 2 patient groups. Similarly, no significant difference was observed in the mean serum titer of HCV RNA or genotype between patients with elevated and normal serum ALT levels. Patients with normal serum ALT levels had significantly ( ) lower scores for P ! .05 inflammation and fibrosis, compared with patients with elevated serum ALT levels. Advanced liver disease, defined as bridging fibrosis and cirrhosis, was observed in only 4 (11.4%) of 35 patients with normal ALT levels (figure 1). This was significantly ( ) less than that observed in persons with P ! .05 elevated ALT levels (37.9%). Minimal changes in liver histology, defined as only portal inflammation with no evidence of piecemeal necrosis and no fibrosis, was observed in 40.0% of patients with normal serum ALT levels but in only 19.0% of those with elevated ALT levels ( ).
Response to therapy in patients with normal and elevated serum ALT levels. Table 2 summarizes the demographic features and biochemical, virologic, and histologic data for each treatment group. No significant differences in mean age, sex, race, mean serum ALT levels, or mean log HCV RNA titer were observed between treatment groups. Twice as many patients with cirrhosis were randomized to the daily therapy group. However, given the small number of patients with cirrhosis included in this study, this difference was not significant.
Response to IFN therapy for the 2 patient groups (those with elevated or persistently normal serum ALT levels) are shown in table 3 as percentages of patients who were negative for HCV RNA in serum after 3, 6, and 18 months of IFN treatment and the rate of sustained virologic response at the end of follow-up (6 months after discontinuation of IFN therapy). Persons with persistently normal serum ALT levels had nearly identical virologic response rates at each time point, compared with persons with elevated ALT levels. For subjects with either elevated or normal serum ALT levels, the percentage who were HCV RNA negative after 3 months of daily IFN therapy (38.3%) was significantly greater ( ) than that of P ! .05 patients treated with IFN TIW (20.8%). In contrast, at 6 months (3 months after the IFN dosing frequency had been reduced from daily to TIW), the percentage of patients who remained HCV RNA negative had declined to 17.0%, similar to findings in persons treated with IFN TIW for 6 months (20.8%). At month 18 (12 months after the IFN dose was reduced to 3 MU TIW), 10.6% and 8.3% of patients remained HCV RNA negative in the daily and TIW treatment groups, respectively. Sustained virologic response was observed in only 9.5% of treated patients.
The factors that predicted sustained virologic response are summarized in table 4. Sustained virologic response was observed significantly more often in persons with a non-type 1 HCV genotype and in persons with !500,000 copies/mL of HCV RNA. In addition, all patients who achieved a sustained virologic response were HCV RNA negative in serum within 3 months of the onset of IFN therapy. In contrast, no significant differences in sustained virologic response were observed with respect to sex, race, severity of liver histology, or IFN dose received.
Adverse events. Eleven patients (29.7%) with a history of persistently normal serum ALT levels developed elevated serum ALT levels during this study. In 3 patients, serum ALT levels became elevated only after IFN therapy was discontinued. Elevations in serum ALT levels were transient in all but 2 patients; 2 patients with persistent elevation in serum ALT levels had fibrosis, according to their liver biopsy results. Elevations in serum ALT levels were not related to IFN dose (4 and 7 patients received daily and TIW therapy, respectively), and one of these patients achieved a sustained virologic response. For patients with a history of elevated serum ALT levels before the onset of IFN therapy, 34% had further elevation of ALT levels during treatment. None achieved a sustained virologic response. Eleven patients voluntarily withdrew from the trial-primarily because of severe flu-like symptoms, depression, or both. The number of patients who did not complete the study was similar for patients with normal (5) and elevated (6) serum ALT levels. Although the number of patients who dropped out of the study was greater in those treated with daily (7) versus TIW (4) IFN, this difference was not significant. None of the patients were dropped from the study secondary to elevations in serum ALT levels, thrombocytopenia, or neutropenia.
Discussion
Some 20%-33% of patients with chronic HCV infection have persistently normal values for serum ALT [1] [2] [3] [4] [5] [6] . This was initially recognized over a decade ago, soon after the identification of HCV and the development of sensitive PCR assays that detect the virus in serum. Early reports describing the clinical, virologic, and histologic characteristics of such persons suggested that the natural history of chronic HCV in persons with persistently normal serum ALT levels was benign and that such patients did not develop cirrhosis [2] [3] [4] [5] . Early reports also suggested that р20% of these patients developed elevations in serum ALT levels during IFN therapy [19] [20] [21] [22] . Thus, in 1996, the National Institutes of Health (NIH) Consensus Development Conference for Management of Hepatitis C recommended that patients with persistently normal serum ALT levels should not be offered IFN [29] . Despite these recommendations, considerable controversy continues about the natural history of HCV infection in these patients and their management. Potential explanations for persistently normal serum ALT levels include the wide variation in normal range for serum ALT levels among laboratories [30, 31] , the limited number of patients in many treatment studies [19] [20] [21] , the demonstration of cirrhosis in some persons with normal ALT levels [9] [10] [11] , and the lack of a clear definition of what constitutes persistently normal serum ALT levels [22] . In the large study by Jamal et al. [9] , these patients were required to have 4 consecutive normal ALT values within 12 months, including 3 normal values in the previous 6 months. In the present study, patients must never have had even a single elevation in serum ALT after a review of all medical records dating back у6 months.
In a recent large study in a predominately Hispanic population in New Mexico, about 27% of 275 consecutive patients with chronic HCV had persistently normal serum ALT levels [9] . Liver histology in these patients was, on average, significantly less severe than in patients with elevated ALT levels. Mean inflammation score was 3.2 versus 4.6, mean fibrosis score was 1.4 versus 2.1, and 6% had cirrhosis, compared with 19% of persons with elevated ALT levels, respectively. Patients with normal ALT levels also had significantly lower serum HCV RNA levels than did those with elevated ALT levels. However, no significant differences were observed between the normal and elevated ALT groups with regard to age, race, sex, risk factors for disease acquisition, symptoms at the time of diagnosis, alcohol consumption, duration of disease, or HCV genotype. The results of our present study (table 1 and figure 1 ) are in close agreement with the results of the study by Jamal et al. [9] and with general trends observed in smaller studies in this population [5-8, 10, 11] . Our study had both a higher percentage of black subjects (47%) and a higher percentage of patients with a normal ALT levels (39%) than that usually reported for the general population with chronic HCV. We believe this reflects the bias of our referral population and the treatment trends of our referring physician population at the time of the study. Few studies have evaluated the efficacy of IFN therapy in persons with persistently normal serum ALT levels. In addition, only a limited number of patients have been evaluated and some studies have not included a control population of persons with elevated ALT levels [19] [20] [21] . Thus, the present study represents the largest controlled IFN treatment trial in this population to date. Our results clearly demonstrate that the likelihood of achieving either viral eradication during IFN therapy or a sustained virologic response was similar in persons with normal or elevated serum ALT levels (table 3) . This observation is in agreement with results of a recent study [23] . Although sustained virologic response was observed in only 8.1% of patients with persistently normal ALT levels, this value was not significantly different than that of persons with elevated ALT levels in the present study (10.3%) or in previous trials using IFN monotherapy [12] [13] [14] [15] [16] [17] .
Serum ALT level has been reported to increase in patients with normal ALT levels during IFN therapy [19, 22] . This was apparently one major reason why the NIH Consensus Development Conference recommended that such patients not be treated with IFN [29] . However, our study shows that persistent elevation in serum ALT levels in these persons is uncommon. Although 11 of 37 patients with normal ALT levels developed elevated ALT levels during IFN therapy, the elevations were transient in all but 2 patients, both of whom had histologic evidence of hepatic fibrosis. Furthermore, 1 patient who had intermittent elevation in serum ALT levels during IFN therapy developed a sustained virologic response. We also found that a further elevation in serum ALT levels above the pretreatment baseline value occurs during the course of IFN therapy in persons with a history of elevated serum ALT levels. Elevations in serum ALT levels were observed in ∼34% of these patients, compared with ∼30% of persons with persistently normal serum ALT levels. These data strongly suggest that persons with chronic HCV infection should not be excluded from IFN therapy simply because of the concern that ALT levels might become elevated during treatment.
It is well established that IFN-ribavirin combination therapy is superior at achieving a sustained virologic response than IFN monotherapy [12, 13, 25] . Indeed, many researchers consider IFN-ribavirin combination therapy the reference standard for treatment of chronic HCV infection. However, there are clinical situations in which ribavirin is contraindicated or cannot be tolerated [32] , such as chronic renal failure, in which persistently normal serum ALT levels are observed in ∼90% of patients [33] . The use of pegylated (peg) IFN monotherapy may prove beneficial for treatment of chronic HCV infection in these clinical scenarios. In recent studies, long-acting peg IFN was superior at achieving a sustained virologic response, when compared with standard IFN monotherapy in patients with chronic HCV infection and elevated serum ALT levels, with or without cirrhosis [34, 35] . On the basis of these results and of our findings in the present study, we anticipate that treatment of persons with chronic HCV infection and persistently normal ALT levels with IFN ribavirin or peg IFN would yield rates for sustained virologic response that are similar to those reported for patients with elevated ALT levels.
Several factors have been identified recently as predictors for sustained virologic response during treatment with IFN monotherapy, IFN ribavirin, or peg IFN [12, 13, 25, [34] [35] [36] : a non-1 HCV genotype, a lower serum level for HCV RNA, and race (white vs. black). The results of the present study are in general agreement with these findings. Patients who achieved sustained virologic response had a significantly lower log titer for serum HCV RNA (4.43 vs. 5.58 copies/mL) and a higher percentage of non-1 HCV genotype (77.8% vs. 22.2%). Black patients also had fewer sustained virologic responses than did whites (33.3% vs. 66.6%), although this difference was not significant (table  4) . The effect of race on virologic response to IFN therapy in persons with chronic HCV infection requires further study.
Given the limited response to IFN and IFN-ribavirin combination therapy, several studies have evaluated the effects of increasing the dose, dosing frequency, or duration of IFN therapy in an attempt to enhance sustained virologic response [18] . However, no studies evaluated the effects of high-dose daily IFN in persons with persistently normal serum ALT levels. The present study clearly demonstrates that significantly more patients with either elevated or persistently normal serum ALT levels become HCV RNA negative during treatment with high daily doses of IFN (table 3) . However, as soon as the IFN dosing frequency was reduced from daily to TIW, many patients developed breakthrough, and the percentage of patients who remained HCV RNA negative was similar to that achieved with TIW dosing. In the end, sustained virologic response was not significantly increased in persons treated with daily versus TIW doses of IFN. Similar observations were made by Fried et al. [37] . In this study, patients with elevated serum ALT levels were treated with high-dose daily IFN for 6 months versus standard IFN monotherapy. Although end-of-treatment response was observed in 66% of those treated with high-dose daily IFN versus 33% of patients treated with standard IFN therapy, longterm sustained response was observed in only 5%-10% of patients, regardless of the IFN dose. These observations clearly demonstrate that high-dose daily IFN regimens do not enhance sustained virologic response in persons with either elevated or persistently normal serum ALT levels and should no longer be used for treatment of chronic HCV infection.
In conclusion, persons with chronic HCV infection and persistently normal serum ALT levels have, on average, milder hepatic histologic damage than do persons with elevated ALT levels. However, ∼10%-15% of those with persistently normal serum ALT levels may develop advanced bridging fibrosis and cirrhosis. Persons with persistently normal serum ALT levels respond to IFN therapy, as do those with elevated ALT levels. However, daily IFN therapy is no more effective at achieving sustained virologic response than TIW dosing, in either patient population. Thus, we recommend that patients with chronic HCV infection and persistently normal ALT levels undergo liver biopsy and be offered treatment, if liver histology is thought to warrant this option.
